CRITICAL INNOVATIONS LLC — Department of Defense SBIR Phase II: CBD212-005
CRITICAL INNOVATIONS LLC — SBIR Phase II award from Department of Defense.
Phase II SBIR prototype / development signal
- Phase II is where Department of Defense funds deeper R&D after feasibility. Incumbents with Phase II history are serious competitors on adjacent topics.
- Use this award as past-performance context and to map customer organizations for STRATFI/TACFI-style transition planning.
- Obligated amount $275,581. Cross-check similar awards in the same agency and technology tags for going-rate context.
- Topic code CBD212-005 links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $275,581
- Agency
- Department of Defense · Office for Chemical and Biological Defense
- Program / Phase
- SBIR · Phase II
- Topic
- CBD212-005
- Solicitation
- 21.2
- NAICS
- —
- Place of performance
- CA
- Period
- 2023-06-23 → 2025-07-02
Description
The Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical) seeks to develop dermal dressing technologies that provide multiple advantages over current wound dressings for treating dermal injuries caused by sulfur mustard. Critical Innovations, Battelle's Biomedical Research Center, the U.S. Army Combat Capabilities Development Command Chemical Biological Center (DEVCOM CBC), and NDA Partners, with consultants Captain David Tanen, MD, FAAEM, FACMT (USN, Ret.) and Dr. Christopher Burns, MD, FACS, have formed a team of medical device experts to address this important medical need. During this Phase II project, our objectives will be to further advance the innovative Succor product. This will include: 1) On-boarding program-specific requirements, goals, and schedule; 2) Producing a pilot run of cGMP production-equivalent devices for use in program testing; 3) Demonstrating product stability, ruggedness, and readiness for the combat environment; 4) Performing a GLP live-animal study of Succor for Sulfur Mustard; and, 5) Maintaining all program-specific regulatory compliance requirements while preparing for upcoming regulatory and transition hurdles.